Advanced Cell Technology Applauds Senate for Bipartisan Support of Stem Cell Legislation; Urges President Bush to Fully Support Embryonic Stem Cell Research; Passage Offers Hope to Millions of Americans.

ALAMEDA, Calif. -- William M. Caldwell, IV, Chief Executive Officer of Advanced Cell Technology, Inc. (OTCBB:ACTC), today praised the US Senate for overwhelming bipartisan support of stem cell legislation (HR 810, S 2754, S 3504), and the advancement of regenerative medicine.

"The passage of this legislation represents the hopes of more than 100 million Americans suffering from cancer, Parkinson's, Alzheimer's, heart disease, diabetes, macular degeneration, spinal cord injuries, and other debilitating diseases and injuries," said Mr. Caldwell. "We commend the Senate for the bipartisan leadership and for moving this most important area of research forward. We ask President Bush to consider the significance of this legislation, and join the Senate in fully supporting embryonic stem cell research. This is an opportunity for the US to reclaim its leadership position in the field of regenerative medicine, and bring treatments and cures to the bedside of millions."

Note to Editors: William M. Caldwell, CEO, is available immediately to comment or address any specific questions related to embryonic stem cell research as it pertains to the legislation being debated. Please contact Noelle Gambill, Chad Griffin Consulting, 805-252-3922.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com.

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended March 31, 2006.

Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.